The financials
NewAmsterdam Pharma Company N.V. by the numbers
NewAmsterdam Pharma Company N.V. (NAMS) reported revenue of $3.0M in Q1 2026 (quarter ended March 31, 2026), up 2.1% from the same quarter a year earlier. That came with net loss of $48M. For the full year FY2025, revenue was $23M (−51% year on year) and net income −$204M.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $3.0M | $3.0M | +2.1% |
| Operating income | −$58M | −$69M | n/a |
| Net income | −$48M | −$40M | n/a |
| Diluted EPS | −$0.40 | −$0.34 | n/a |